Aptamer Sciences Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Aptamer Sciences Inc. - overview
Established
2011
Location
Pohang, Gyeongbuk, South Korea
Primary Industry
Biotechnology
About
Founded in 2011 and based in South Korea, Aptamer Sciences Inc. is a biotechnology company focused on commercializing technologies for the analysis of proteins. In 2016, Aptamer Sciences Inc. raised USD 4 million in venture funding from new investor Brightstar Partners.
The company applies aptamer-based technology to develop new drugs for various diseases. The company's product pipeline includes ApDC for solid rock and brain tumor, Chimeric Aptamer for Parkinson's disease and immune cancer, and aptamer for diabetes and covid-19. The company also provides services including aptamer synthesis services and aptamer excavation services.
Current Investors
G.N.TECH Venture Capital, Kiwoom Investment, Brightstar Partners
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.aptsci.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Aptamer Sciences Inc. - timeline of key events
Aptamer Sciences Inc. - financials
| Fiscal Year Ended | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 166,643,220 | 276,496,903 | 407,591,386 | 228,506,094 | 269,275,078 | - | - | - |
| % Revenue Growth (YoY) | - | 65.9% | 47.4% | (43.9%) | 17.8% | - | - | - |
| EBITDA (USD) | (1,773,728,307) | (3,179,828,641) | (3,009,964,780) | (3,574,875,968) | (3,628,228,305) | - | - | - |
| Operating Income (USD) | (1,915,164,460) | (3,375,624,884) | (3,291,562,116) | (3,922,978,968) | (4,067,106,305) | - | - | - |
| Operating Margin | (1149.3%) | (1220.9%) | (807.6%) | (1716.8%) | (1510.4%) | - | - | - |
| % EBITDA Margin | (1064.4%) | (1150.0%) | (738.5%) | (1564.5%) | (1347.4%) | - | - | - |
| NET Income (USD) | (1,887,312,001) | (7,344,671,390) | (3,852,555,444) | (3,843,399,617) | (3,831,058,596) | - | - | - |
| % Net Margin | (1132.5%) | (2656.3%) | (945.2%) | (1682.0%) | (1422.7%) | - | - | - |
Aptamer Sciences Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.